A 78-Year-Old Man With Metastatic Melanoma and a 67-Year-Old Woman With Stage IV Melanoma : Episode 2
Common Clinical Presentations of Metastatic Melanoma
Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.
EP: 1.Case Presentation: A 78-Year-Old Man With Metastatic Melanoma
Now Viewing
EP: 2.Common Clinical Presentations of Metastatic Melanoma
EP: 3.Significance of Biomarker and Genetic Testing in Diagnosing Metastatic Melanoma
EP: 4.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma
EP: 5.The Role of Lymphocyte-Activation Gene 3 (LAG-3) in Metastatic Melanoma
EP: 6.Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial
EP: 7.IO Monotherapy Versus Combination Dual IO Therapy for the First-Line Treatment of Metastatic Melanoma
EP: 8.Key Trial Data in the Frontline Treatment of Metastatic Melanoma
EP: 9.Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy
EP: 10.Case Presentation: A 67-Year-Old Woman With Stage IV Melanoma
EP: 11.Available First-Line Systemic Therapy Options for Patients With Metastatic Melanoma with a BRAF Mutation
EP: 12.Nivolumab/Ipilimumab Followed by Dabrafenib/Trametinib in Metastatic Melanoma: Data From the DREAMseq Trial
EP: 13.Second-Line Treatment Options for Patients With Metastatic or Unresectable Melanoma After Disease Progression
EP: 14.Clinical Pearls on the Treatment of Metastatic and Unresectable Melanoma
Recent Videos
Related Content
Similar Efficacy in Melanoma Shown in Indirect Comparison of PD-1/LAG3 vs PD-1/CTLA-4
July 16th 2024Article
During a Case-Based Roundtable® event, Michael A. Postow, MD, discussed an indirect treatment comparison of nivolumab plus relatlimab vs nivolumab plus ipilimumab in patients with advanced melanoma in the second article of a 2-part series.
Read More
